Please login to the form below

Not currently logged in
Email:
Password:

US Congress

This page shows the latest US Congress news and features for those working in and with pharma, biotech and healthcare.

It's the guns, stupid

It's the guns, stupid

Gun violence in the US – a public health issue – can be better understood through three points. ... The first one is actually simpler to answer. In 1996, the US congress passed the Dickey Amendment which was, effectively, a response to the Centers

Latest news

  • Roche says ‘discovery proteomics’ is heading for clinical trials Roche says ‘discovery proteomics’ is heading for clinical trials

    A study presented at the Mass Spectrometry Applications to the Clinical Lab (MSACL) congress in the US last week by Roche and Biognosys scientists looked at how ‘discovery proteomics’ performed in

  • GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

    This included a $3bn fine imposed on GSK after it was caught promoting Advair off-label in the US, with a corporate integrity agreement imposed on it by US regulators. ... It will also return to paying travel costs for HCPs to attend GSK’s own

  • FDA moves to tackle orphan designation backlog FDA moves to tackle orphan designation backlog

    The US regulator's Orphan Drug Modernisation Plan aims to eliminate the waiting list, and is the first development under the FDA's new Medical Innovation Development Plan. ... Congress gave us tools to incentivise the development of novel therapies for

  • The tribe has spoken The tribe has spoken

    Who gets to decide which profit margin is acceptable? Reality TV has given us countless catchphrases and memorable pop culture idioms and Jeff Probst's final words to the ousted Survivor ... Forget, for a moment, about the fact that for this to happen it

  • Alexion's rare bone disorder therapy rejected by NICE Alexion's rare bone disorder therapy rejected by NICE

    In the US the drug has been priced at an average $285, 000 a year - well below the level expected by analysts - with some suggesting the company may have been spooked ... The US decision may signal that Alexion is prepared to be flexible on Strensiq's

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    A US survey that has been undertaken every year since the early 1990s provides some illumination as to the specialties that residents and fellows completing their training in New York State ... A brief glance at the programme for the major US haematology

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Attracting doctors to low-demand specialties: A role for industry?

    A US survey that has been undertaken every year since the early 1990s provides some illumination as to the specialties that residents and fellows completing their training in New York State ... A brief glance at the programme for the major US haematology

  • EULAR Annual European Congress of Rheumatology 2017

    Join us at EULAR Congress 2017 in Madrid, 14-17 June. We are delighted to be attending and presenting at this year’s EULAR Annual European Congress of Rheumatology in June.

  • Research Partnership

    Research Partnership is today expanding its US operations across both the West and East Coast. ... Visit us on stand number 14. Join us at EULAR Congress 2017 in Madrid, 14-17 June.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics